Cortisol’s Clock: Rethinking Diagnosis and Therapeutic Drug Monitoring in Cushing Syndrome
A new review in The Journal of Clinical Endocrinology & Metabolism examines the critical role of cortisol circadian rhythm assessment in diagnosing and managing endogenous Cushing syndrome (CS). This rare endocrine disorder, characterized by chronic excessive cortisol exposure, is often underdiagnosed due to non-specific symptoms and complex biochemical testing. The article highlights the limitations of traditional single-time-point cortisol measurements or cumulative tests, which fail to capture the full daily rhythm of hormone fluctuations. The authors argue for a paradigm shift towards continuous monitoring techniques that can assess the disrupted circadian secretion pattern, a key feature of the disease. This approach could significantly improve diagnostic accuracy, especially in milder cases, and provide a more nuanced target for therapeutic drug monitoring to guide treatment efficacy and personalize medicine strategies.
Study Significance: For pharmacologists and clinicians, this review underscores a move beyond static pharmacokinetic measures towards dynamic, rhythm-based biomarkers for complex endocrine disorders. It suggests that optimizing drug therapy for CS may depend less on simply lowering total cortisol exposure and more on restoring its natural circadian profile, a concept with implications for dosing schedules and novel drug delivery systems. This focus on chronopharmacology and personalized therapeutic windows could refine clinical trial endpoints and improve long-term patient outcomes by aligning treatment with the body’s intrinsic biological rhythms.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
